Clinical Trial of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, blinded, placebo-controlled clinical trial to evaluate
the protective efficacy, safety and immunogenicity of one dose of the SARS-CoV-2 variant
(Omicron BA.5) mRNA vaccine in people aged 18 years and older who had received two or three
doses of inactivated COVID-19 vaccine.
Phase:
N/A
Details
Lead Sponsor:
AIM Vaccine Co., Ltd.
Collaborators:
First Affiliated Hospital Bengbu Medical College Ningbo Rongan Biological Pharmaceutical Co. Ltd.